← Back to Search

Osteopathic Manipulative Therapy (OMT) for Migraine

Waitlist Available
Led By Abby Rhoads, DO
Research Sponsored by St. Luke's Hospital, Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No physical therapy for headaches, neck pain or for trapezius muscle during 12 weeks for both control and intervention group
Age: 18-50
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This study is evaluating whether Osteopathic Manipulative Therapy (OMT) can reduce migraine disability and severity scores when compared to standard of care including prophylactic pharmacological agents.

Eligible Conditions
  • Migraine
  • Headache Disorders

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
There was no physical therapy for headaches, neck pain, or trapezius muscle during 12 weeks for both the control and intervention groups.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reduction in the Headache Impact Test (HIT-6) score in OMT intervention group compared to control group.
Reduction in the Migraine Disability Test (MIDAS) score in the OMT interventional group compared to control group.
Secondary outcome measures
Headache Days
Pain scale

Trial Design

2Treatment groups
Experimental Treatment
Group I: Interventional Group receiving Osteopathic Manipulative Therapy (OMT)Experimental Treatment1 Intervention
70 patients with chronic migraine who consent to OMT will receive four standardized osteopathic manipulative treatment protocol over the course of twelve weeks at week 0,2,6,10. MIDAS and HIT-6 Questionnaires will be obtained at time of consent prior to first treatment and again at the conclusion of treatment period of twelve weeks.
Group II: Control Group with Standard of CareExperimental Treatment1 Intervention
70 patients with the diagnosis of migraine headache who are receiving the standard of care medications will complete a MIDAS and HIT-6 questionnaire at week 0 and week 12. A new prophylactic medication may be started at time of initial questionnaires and the patient can be on up to two prophylactic medications, with no changes during the 12 week period.

Find a Location

Who is running the clinical trial?

St. Luke's Hospital, PennsylvaniaLead Sponsor
18 Previous Clinical Trials
3,086 Total Patients Enrolled
Abby Rhoads, DOPrincipal InvestigatorSt. Luke's Hospital and Health Network, Pennsylvania

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
St. Luke's University Health Network
What portion of applicants met pre-screening criteria?
Met criteria
~22 spots leftby Apr 2025